Uj vakcinak lehetosege a jovo szazad elso negyedeben

Translated title of the contribution: Possible new vaccinations in the first quarter of the next century

E. Gönczöl, K. Berencsi, V. Endrész, K. Burián, Z. Gyulai, L. Kari, D. Virók

Research output: Contribution to journalArticle

Abstract

The WHO-directed vaccination campaign against smallpox in the fate 1970s led to the eradication of the variola virus and made the anti-smallpox vaccination unnecessary. The currently available vaccines have also provided substantial protection against various infectious diseases. 'Conventional' vaccines (containing attenuated live or inactivated pathogens or their immunogenic components), however, would not afford protection against many bacterium-, virus- or parasite-caused diseases, or their use would not meet the necessary safety requirements. The increasing knowledge in molecular biology relating to these pathogens and basic immunology, and also revolutionary progress in gene technology, have provided alternative possibilities for the development of vaccines against such pathogens. One of the alternatives is the production and use of bacterial or viral proteins engineered by expression vectors (bacterium, virus, yeast or plant), which would induce humoral immune responses in the immunised individuals. Another alternative is the use of recombinant vectors themselves (bacterium, virus or plasmid) for immunisation, which would induce not only humoral, but also cellular immune response against the inserted gene product. The most promising vectors are the virus vectors, which do not fully replicate, but express early genes in human cells, and the eukaryotic plasmid vectors (DNA immunisation). The application of molecular biology in preventive approaches, will soon lead to the development of a number of effective and safe vaccines against severe human and animal diseases.

Original languageHungarian
Pages (from-to)88-95
Number of pages8
JournalLege Artis Medicinae
Volume9
Issue number2
Publication statusPublished - 1999

Fingerprint

Vaccination
Viruses
Smallpox
Vaccines
Bacteria
Molecular Biology
Immunization
Plasmids
Variola virus
Genes
Immunization Programs
Attenuated Vaccines
Animal Diseases
Bacterial Proteins
Eukaryotic Cells
Viral Proteins
Humoral Immunity
Allergy and Immunology
Cellular Immunity
Communicable Diseases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Uj vakcinak lehetosege a jovo szazad elso negyedeben. / Gönczöl, E.; Berencsi, K.; Endrész, V.; Burián, K.; Gyulai, Z.; Kari, L.; Virók, D.

In: Lege Artis Medicinae, Vol. 9, No. 2, 1999, p. 88-95.

Research output: Contribution to journalArticle

@article{c7c55256dd1c4b93afc11bbb2eda5e9a,
title = "Uj vakcinak lehetosege a jovo szazad elso negyedeben",
abstract = "The WHO-directed vaccination campaign against smallpox in the fate 1970s led to the eradication of the variola virus and made the anti-smallpox vaccination unnecessary. The currently available vaccines have also provided substantial protection against various infectious diseases. 'Conventional' vaccines (containing attenuated live or inactivated pathogens or their immunogenic components), however, would not afford protection against many bacterium-, virus- or parasite-caused diseases, or their use would not meet the necessary safety requirements. The increasing knowledge in molecular biology relating to these pathogens and basic immunology, and also revolutionary progress in gene technology, have provided alternative possibilities for the development of vaccines against such pathogens. One of the alternatives is the production and use of bacterial or viral proteins engineered by expression vectors (bacterium, virus, yeast or plant), which would induce humoral immune responses in the immunised individuals. Another alternative is the use of recombinant vectors themselves (bacterium, virus or plasmid) for immunisation, which would induce not only humoral, but also cellular immune response against the inserted gene product. The most promising vectors are the virus vectors, which do not fully replicate, but express early genes in human cells, and the eukaryotic plasmid vectors (DNA immunisation). The application of molecular biology in preventive approaches, will soon lead to the development of a number of effective and safe vaccines against severe human and animal diseases.",
keywords = "DNA-immunisation, New vaccines, Recombinant vaccines",
author = "E. G{\"o}ncz{\"o}l and K. Berencsi and V. Endr{\'e}sz and K. Buri{\'a}n and Z. Gyulai and L. Kari and D. Vir{\'o}k",
year = "1999",
language = "Hungarian",
volume = "9",
pages = "88--95",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "2",

}

TY - JOUR

T1 - Uj vakcinak lehetosege a jovo szazad elso negyedeben

AU - Gönczöl, E.

AU - Berencsi, K.

AU - Endrész, V.

AU - Burián, K.

AU - Gyulai, Z.

AU - Kari, L.

AU - Virók, D.

PY - 1999

Y1 - 1999

N2 - The WHO-directed vaccination campaign against smallpox in the fate 1970s led to the eradication of the variola virus and made the anti-smallpox vaccination unnecessary. The currently available vaccines have also provided substantial protection against various infectious diseases. 'Conventional' vaccines (containing attenuated live or inactivated pathogens or their immunogenic components), however, would not afford protection against many bacterium-, virus- or parasite-caused diseases, or their use would not meet the necessary safety requirements. The increasing knowledge in molecular biology relating to these pathogens and basic immunology, and also revolutionary progress in gene technology, have provided alternative possibilities for the development of vaccines against such pathogens. One of the alternatives is the production and use of bacterial or viral proteins engineered by expression vectors (bacterium, virus, yeast or plant), which would induce humoral immune responses in the immunised individuals. Another alternative is the use of recombinant vectors themselves (bacterium, virus or plasmid) for immunisation, which would induce not only humoral, but also cellular immune response against the inserted gene product. The most promising vectors are the virus vectors, which do not fully replicate, but express early genes in human cells, and the eukaryotic plasmid vectors (DNA immunisation). The application of molecular biology in preventive approaches, will soon lead to the development of a number of effective and safe vaccines against severe human and animal diseases.

AB - The WHO-directed vaccination campaign against smallpox in the fate 1970s led to the eradication of the variola virus and made the anti-smallpox vaccination unnecessary. The currently available vaccines have also provided substantial protection against various infectious diseases. 'Conventional' vaccines (containing attenuated live or inactivated pathogens or their immunogenic components), however, would not afford protection against many bacterium-, virus- or parasite-caused diseases, or their use would not meet the necessary safety requirements. The increasing knowledge in molecular biology relating to these pathogens and basic immunology, and also revolutionary progress in gene technology, have provided alternative possibilities for the development of vaccines against such pathogens. One of the alternatives is the production and use of bacterial or viral proteins engineered by expression vectors (bacterium, virus, yeast or plant), which would induce humoral immune responses in the immunised individuals. Another alternative is the use of recombinant vectors themselves (bacterium, virus or plasmid) for immunisation, which would induce not only humoral, but also cellular immune response against the inserted gene product. The most promising vectors are the virus vectors, which do not fully replicate, but express early genes in human cells, and the eukaryotic plasmid vectors (DNA immunisation). The application of molecular biology in preventive approaches, will soon lead to the development of a number of effective and safe vaccines against severe human and animal diseases.

KW - DNA-immunisation

KW - New vaccines

KW - Recombinant vaccines

UR - http://www.scopus.com/inward/record.url?scp=0032939819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032939819&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032939819

VL - 9

SP - 88

EP - 95

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 2

ER -